20 research outputs found
Injectable gellan gum-based nanoparticles-loaded system for the local delivery of vancomycin in osteomyelitis treatment
Infection spreading in the skeletal system
leading to osteomyelitis can be prevented by the prolonged
administration of antibiotics in high doses. However systemic
antibiotherapy, besides its inconvenience and often
low efficacy, provokes numerous side effects. Thus, we
formulated a new injectable nanoparticle-loaded system for
the local delivery of vancomycin (Vanc) applied in a
minimally-invasive way. Vanc was encapsulated in poly(Llactide-
co-glycolide) nanoparticles (NPs) by double-emulsification.
The size (258 ± 11 nm), polydispersity index
(0.240 ± 0.003) and surface potential (-25.9 ± 0.2 mV)
of NPs were determined by dynamic light scattering and
capillary electrophoresis measurements. They have a
spherical morphology and a smooth topography as
observed using atomic force microscopy. Vanc loading and
encapsulation efficiencies were 8.8 ± 0.1 and
55.2 ± 0.5 %, respectively, based on fluorescence spectroscopy
assays. In order to ensure injectability, NPs were
suspended in gellan gum and cross-linked with ; also a
portion of dissolved antibiotic was added to the system.
The resulting system was found to be injectable (extrusion
force 11.3 ± 1.1 N), reassembled its structure after
breaking as shown by rheology tests and ensured required
burst release followed by sustained Vanc delivery. The
system was cytocompatible with osteoblast-like MG-63
cells (no significant impact on cells’ viability was detected). Growth of Staphylococcus spp. reference strains
and also those isolated from osteomyelitic joints was
inhibited in contact with the injectable system. As a result
we obtained a biocompatible system displaying ease of
application (low extrusion force), self-healing ability after
disruption, adjustable drug release and antimicrobial
properties
Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus
The pemphigus group comprises the autoimmune intraepidermal blistering diseases classically divided into two major types: pemphigus vulgaris and pemphigus foliaceous. Pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus are rarer forms that present some clinical, histological and immunopathological characteristics that are different from the classical types. These are reviewed in this article. Future research may help definitively to locate the position of these forms in the pemphigus group, especially with regard to pemphigus herpetiformis and the IgG/ IgA pemphigus.Universidade Federal de SĂŁo Paulo (UNIFESP), Escola Paulista de Medicina (EPM) Dermatology DepartmentUniversidade Federal de SĂŁo Paulo (UNIFESP), Escola Paulista de Medicina (EPM) Dermatology and Pathology DepartmentsUNIFESP, EPM, Dermatology DepartmentUNIFESP, EPM, Dermatology and Pathology DepartmentsSciEL
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.
OBJECTIVE: We aimed to develop consensus-based recommendations for streamlining medical communication among various health care professionals, to improve accuracy of diagnosis and treatment, and to facilitate future investigations for mucous membrane pemphigoid. PARTICIPANTS: Because of the highly specific nature of this group of diseases, the 26 invited participants included either international scholars in the field of mucous membrane pemphigoid or experts in cutaneous pharmacology representing the 3 medical disciplines ophthalmology, oral medicine, and dermatology. EVIDENCE: The first author (L.S.C.) conducted a literature search. Based on the information obtained, international experts who had contributed to the literature in the clinical care, diagnosis, and laboratory investigation for mucous membrane pemphigoid were invited to participate in a consensus meeting aimed at developing a consensus statement. CONSENSUS PROCESS: A consensus meeting was convened and conducted on May 10, 1999, in Chicago, Ill, to discuss the relevant issues. The first author drafted the statement based on the consensus developed at the meeting and the participants' written comments. The draft was submitted to all participants for 3 separate rounds of review, and disagreements were reconciled based on literature evidence. The third and final statement incorporated all relevant evidence obtained in the literature search and the consensus developed by the participants. The final statement was approved and endorsed by all 26 participants. CONCLUSIONS: Specific consensus-based recommendations were made regarding the definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators for mucous membrane pemphigoid. A system of standard reporting for these patients was proposed to facilitate a uniform data collection